Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies

被引：0
|
作者：
Sharon Walmsley
Don E. Smith
Miguel Górgolas
Pedro E. Cahn
Thomas Lutz
Karine Lacombe
Princy N. Kumar
Brian Wynne
Richard Grove
Gilda Bontempo
Riya Moodley
Chinyere Okoli
Michelle Kisare
Bryn Jones
Andrew Clark
Mounir Ait-Khaled
机构：
[1] University Health Network,
[2] Albion Centre,undefined
[3] Fundación Jiménez Díaz,undefined
[4] Universidad Autónoma de Madrid,undefined
[5] Fundación Huésped,undefined
[6] Infektiologikum,undefined
[7] Hôpital Saint-Antoine,undefined
[8] Georgetown University Medical Center,undefined
[9] ViiV Healthcare,undefined
[10] GSK,undefined
[11] ViiV Healthcare,undefined
[12] ViiV Healthcare,undefined
来源：
AIDS Research and Therapy | / 21卷
关键词：
Aging; Comorbidity; DTG/3TC; HIV-1; Polypharmacy; Single-tablet regimen; Suppressed switch;  ≥ 50 years;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
相关论文
共 50 条
  • [21] Safety and effectiveness of switching to Abacavir/Lamivudine plus rilpivirine for maintenance therapy in virologically suppressed HIV-1 individuals in Singapore (SEALS)
    Lim, Z. C.
    Hoo, G. S.
    Ang, J. H.
    Teng, C. B.
    Ang, L. W.
    Lee, C. C.
    Leo, Y. S.
    Law, H. L.
    Ng, O. T.
    Wong, C. S.
    AIDS RESEARCH AND THERAPY, 2021, 18 (01)
  • [22] Safety and effectiveness of switching to Abacavir/Lamivudine plus rilpivirine for maintenance therapy in virologically suppressed HIV-1 individuals in Singapore (SEALS)
    Z. C. Lim
    G. S. Hoo
    J. H. Ang
    C. B. Teng
    L. W. Ang
    C. C. Lee
    Y. S. Leo
    H. L. Law
    O. T. Ng
    C. S. Wong
    AIDS Research and Therapy, 18
  • [23] Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naive, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety
    Cento, Valeria
    Perno, Carlo Federico
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2020, 20 : 228 - 237
  • [24] Quantitation of cellular HIV-1 DNA levels by droplet digital PCR in virologically-suppressed patients switching to dolutegravir plus lamivudine: a prospective study
    Lombardi, F.
    Belmonti, S.
    Borghetti, A.
    Ciccullo, A.
    Baldin, G.
    Emiliozzi, A.
    Moschese, D.
    Cauda, R.
    Di Giambenedetto, S.
    HIV MEDICINE, 2019, 20 : 77 - 77
  • [25] Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial
    Maggiolo, Franco
    Rizzardini, Giuliano
    Molina, Jean-Michel
    Pulido, Federico
    De Wit, Stephane
    Vandekerckhove, Linos
    Berenguer, Juan
    D'Antoni, Michelle L.
    Blair, Christiana
    Chuck, Susan K.
    Piontkowsky, David
    Martin, Hal
    Haubrich, Richard
    McNicholl, Ian R.
    Gallant, Joel
    INFECTIOUS DISEASES AND THERAPY, 2021, 10 (02) : 775 - 788
  • [26] Dolutegravir monotherapy versus dolutegravir/abacavir/lamivudine for HIV-1-infected virologically suppressed patients: results from the randomized non-inferiority MONCAY trial
    Hocqueloux, L.
    Allavena, C.
    Prazuck, T.
    Bernard, L.
    Sunder, S.
    Esnault, J. -L.
    Rey, D.
    Le Moal, G.
    Roncato-Saberan, M.
    Andre, M.
    Billaud, E.
    Avettand-Fenoel, V.
    Valery, A.
    Raffi, F.
    Parienti, J. -J.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21 : 6 - 6
  • [27] Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial
    Franco Maggiolo
    Giuliano Rizzardini
    Jean-Michel Molina
    Federico Pulido
    Stephane De Wit
    Linos Vandekerckhove
    Juan Berenguer
    Michelle L. D’Antoni
    Christiana Blair
    Susan K. Chuck
    David Piontkowsky
    Hal Martin
    Richard Haubrich
    Ian R. McNicholl
    Joel Gallant
    Infectious Diseases and Therapy, 2021, 10 : 775 - 788
  • [28] Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study
    Cahn, Pedro
    Rolon, Maria Jose
    Figueroa, Maria Ines
    Gun, Ana
    Patterson, Patricia
    Sued, Omar
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2017, 20
  • [29] SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen (vol 56, pg 1637, 2013)
    Campo, R.
    DeJesus, E.
    Bredeek, U. F.
    Henry, K.
    Khanlou, H.
    Logue, K.
    CLINICAL INFECTIOUS DISEASES, 2013, 57 (05)
  • [30] Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
    Molina, Jean-Michel
    Ward, Douglas
    Brar, Indira
    Mills, Anthony
    Stellbrink, Hans Juergen
    Lopez-Cortes, Luis
    Ruane, Peter
    Podzamczer, Daniel
    Brinson, Cynthia
    Custodio, Joseph
    Liu, Hui
    Andreatta, Kristen
    Martin, Hal
    Cheng, Andrew
    Quirk, Erin
    LANCET HIV, 2018, 5 (07): : E357 - E365
12345